Remove 2019 Remove Pharmaceutical Companies Remove Vaccines
article thumbnail

Pfizer: Pharma needs a business strategy for a digital world

pharmaphorum

Its chief digital and technology officer Lidia Fonseca offered a fascinating insight into how one biggest pharmaceutical companies – and one of those most closely associated with the pandemic (alongside the likes of BioNTech, Moderna and AstraZeneca) – has been transforming itself. Digital fluency and change.

article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nine for 2021: The COVID-19 legacy

pharmaphorum

One bright spot in an otherwise dreadful year: the pharmaceutical industry has discovered it can do things it never dreamed possible. Anyone who proposed that a novel, deadly virus would spread, with a vaccine developed demonstrating 95% efficacy, and approved for patients in less than a year would have been scoffed at.

Hospitals 105
article thumbnail

Pharma sector reels as UK Government doubles VPAS payback rate on NHS drugs

Pharmaceutical Technology

For 2019–23, this was capped at 2% per year. During 2019–21, when sales being close to predicted levels resulted in single-digit payback rates, the scheme was relatively popular with the pharma sector. At this punitive percentage, VPAS member companies may be required to pay back up to GBP3.3 billion ($4.1 billion) to the NHS.

article thumbnail

Pharma’s climate change vulnerability and opportunity

pharmaphorum

Rising global temperatures will, for example, enhance the spread of mosquito-borne diseases like malaria and Zika, increasing the need for effective vaccines. In 2019, the pharmaceutical industry produced 48.55 But preparing to adapt to the phenomenon presents an opportunity as well as a challenge. Responsibility .

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

article thumbnail

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

STAT

Pharmaceutical companies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports.  A As of 2019, about 1.9 Or you may want to take stock of your life.

FDA 98